Immune-based mutation classification enables neoantigen prioritization and immune feature discovery in cancer immunotherapy
Genetic mutations lead to the production of mutated proteins from which peptides are presented to T cells as cancer neoantigens. Evidence suggests that T cells that target neoantigens are the main mediators of effective cancer immunotherapies. Although algorithms have been used to predict neoantigen...
Main Authors: | Peng Bai, Yongzheng Li, Qiuping Zhou, Jiaqi Xia, Peng-Cheng Wei, Hexiang Deng, Min Wu, Sanny K. Chan, John W. Kappler, Yu Zhou, Eric Tran, Philippa Marrack, Lei Yin |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2021-01-01
|
Series: | OncoImmunology |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/2162402X.2020.1868130 |
Similar Items
-
NEPdb: A Database of T-Cell Experimentally-Validated Neoantigens and Pan-Cancer Predicted Neoepitopes for Cancer Immunotherapy
by: Jiaqi Xia, et al.
Published: (2021-04-01) -
Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies
by: Zijun Y. Xu-Monette, et al.
Published: (2019-10-01) -
Neoantigen characteristics in the context of the complete predicted MHC class I self-immunopeptidome
by: Scott D. Brown, et al.
Published: (2019-03-01) -
Pre‐existing heterologous T‐cell immunity and neoantigen immunogenicity
by: Qibin Leng, et al.
Published: (2020-01-01) -
Structure Based Prediction of Neoantigen Immunogenicity
by: Timothy P. Riley, et al.
Published: (2019-08-01)